コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 from a nucleotide to a hydroxyl group of an aminoglycoside antibiotic.
2 stem-loop by neomycin, a naturally occurring aminoglycoside antibiotic.
3 on during the biosynthesis of gentamicin, an aminoglycoside antibiotic.
4 the active site, followed by binding of the aminoglycoside antibiotic.
5 ATN) produced by chemotherapeutic agents and aminoglycoside antibiotics.
6 e important bacterial resistance enzymes for aminoglycoside antibiotics.
7 zyme, and it modifies more than 10 different aminoglycoside antibiotics.
8 lement) RNA was measured upon titration with aminoglycoside antibiotics.
9 oacoustic emissions, the salicylates and the aminoglycoside antibiotics.
10 hat are protected by tRNA, 50 S subunits, or aminoglycoside antibiotics.
11 inner ear can occur after damage induced by aminoglycoside antibiotics.
12 e structures are candidate receptors for the aminoglycoside antibiotics.
13 rRNA region comprises the natural target for aminoglycoside antibiotics.
14 isepamicin remains one of the more effective aminoglycoside antibiotics.
15 S rRNA constitutes the functional target for aminoglycoside antibiotics.
16 pect to their abilities to specifically bind aminoglycoside antibiotics.
17 endent O-phosphorylation of a broad range of aminoglycoside antibiotics.
18 hrotoxicity associated with the use of these aminoglycoside antibiotics.
19 ir predecessors during prolonged exposure to aminoglycoside antibiotics.
20 hlear hair cells in guinea pigs treated with aminoglycoside antibiotics.
21 tion, the oligonucleotide binds specifically aminoglycoside antibiotics.
22 ult, aging, and damage from intense sound or aminoglycoside antibiotics.
23 variant were identified, all of whom avoided aminoglycoside antibiotics.
24 high-level resistance to a broad spectrum of aminoglycoside antibiotics.
25 ts induced on lipid membranes by amphiphilic aminoglycoside antibiotics.
26 fusion system, with decreased resistance to aminoglycoside antibiotics.
27 ce, to develop a sensor for the detection of aminoglycoside antibiotics.
28 th ototoxic drugs, including the widely used aminoglycoside antibiotics.
29 iosynthesis of 2-deoxystreptamine-containing aminoglycoside antibiotics.
30 miting factor in the clinical application of aminoglycoside antibiotics.
31 a new paradigm for the development of safer aminoglycoside antibiotics.
32 anism by which bacteria confer resistance to aminoglycoside antibiotics.
33 ment (SELEX) to isolate RNA aptamers against aminoglycoside antibiotics.
34 cells resistant to hydrogen peroxide and to aminoglycoside antibiotics.
35 es the 2-deoxystreptamine ring common to all aminoglycoside antibiotics.
36 -deoxystreptamine ring (2-DOS) common to all aminoglycoside antibiotics.
37 pression causes hypersensitivity to multiple aminoglycoside antibiotics.
38 ly emerged with applications in the field of aminoglycoside antibiotics.
39 domonas aeruginosa, catalyzes acetylation of aminoglycoside antibiotics.
40 ) are common bacterial resistance enzymes to aminoglycoside antibiotics.
41 ens catalyzes adenylation and acetylation of aminoglycoside antibiotics.
42 ear are damaged by intense noise, aging, and aminoglycoside antibiotics.
43 action of aminoglycoside antibiotics with an aminoglycoside antibiotic 3'-phosphotransferase [APH(3')
44 phosphotransferases [APH(3')s] phosphorylate aminoglycoside antibiotics, a reaction that inactivates
45 sh lateral line hair cells after exposure to aminoglycoside antibiotics, a well characterized hair ce
46 boxamide, 1 (ORC-001), as protective against aminoglycoside antibiotic (AGA)-induced hair cell death.
47 gs can be extremely useful in developing new aminoglycoside antibiotics against resistant bacteria.
48 uvant activity, potentiating the efficacy of aminoglycoside antibiotics against several species of re
49 rial activity as neomycin, a clinically used aminoglycoside antibiotic, against Escherichia coli, Sta
52 ted that bactericidal antibiotics, including aminoglycoside antibiotics (AGAs), and toxic small molec
53 the determined conformations of enzyme-bound aminoglycoside antibiotics also suggested that interacti
55 values of the pKa of the amino groups of the aminoglycoside antibiotic amikacin and of its acetylated
58 ization of RNA aptamers that bind cofactors, aminoglycoside antibiotics, amino acids and peptides wit
59 from acetyl coenzyme A to substrates such as aminoglycoside antibiotics, amino acids, polyamines, pep
61 inhibition patterns indicate that binding of aminoglycoside antibiotic and ATP occurs in a random man
62 l model for specific ribosome recognition by aminoglycoside antibiotics and a possible mechanism for
63 ma membrane, and increased susceptibility to aminoglycoside antibiotics and cationic antimicrobials.
65 saccharide Pel, which protects bacteria from aminoglycoside antibiotics and contributes to biofilm ar
66 The suf13-1 suppressor alters sensitivity to aminoglycoside antibiotics and reduces the accumulation
67 ansferase IIIa [APH(3')-IIIa] phosphorylates aminoglycoside antibiotics and renders them ineffective
70 te RNA oligonucleotide specifically binds to aminoglycoside antibiotics and the structure of the RNA-
72 Recent emergence of microbial resistance to aminoglycoside antibiotics, and the documented cytotoxic
74 name ZEMDRI (Cipla Therapeutics), is a novel aminoglycoside antibiotic approved by the U.S. Food and
75 ranslational readthrough of stop codons, the aminoglycoside antibiotics are currently being tested fo
82 tural inspection of Kdo(2)-lipid A suggested aminoglycoside antibiotics as potential inhibitors for H
83 t, in the absence of metal ions, a number of aminoglycoside antibiotics at 10 mM concentration promot
87 sses of ototoxic drugs are cisplatin and the aminoglycoside antibiotics, both of which are toxic to m
88 the geometrical and electrostatic nature of aminoglycoside antibiotics bound to a modifying enzyme a
90 ymes that cause high levels of resistance to aminoglycoside antibiotics by the organisms that harbor
93 addition, commonly used antibiotics, such as aminoglycoside antibiotics, can lead to disruption of ot
94 ue member of the 2-deoxystreptamine class of aminoglycoside antibiotics characterized by a monosubsti
95 f Pseudomonas aeruginosa that is a potential aminoglycoside antibiotic combination therapy target.
97 igate the interaction between tobramycin, an aminoglycoside antibiotic commonly administered to CF pa
99 almost half of a century, we have known that aminoglycoside antibiotics corrupt ribosomes, causing tr
100 the design and development of a new class of aminoglycoside antibiotics culminating in the discovery
101 and mechanism of TA toxin action drawn from aminoglycoside antibiotics: Doc toxicity is the result o
103 555A>G predisposes to hearing loss following aminoglycoside antibiotic exposure in an idiosyncratic d
104 in hair cell death following noise exposure, aminoglycoside antibiotic exposure, as well as in age-re
106 point for the development of next-generation aminoglycoside antibiotics for the treatment of multidru
107 inding could change our understanding of how aminoglycoside antibiotics function, with interruption o
112 from 1-day-old chicks and incubated with the aminoglycoside antibiotics gentamicin or neomycin (both
118 n mimicked the effects of treatment with the aminoglycoside antibiotic hygromycin B (HygB): Both Doc
119 ues, such as hyperosmolarity and presence of aminoglycoside antibiotics, (ii) narrowed their metaboli
120 The first enzyme-bound conformation of an aminoglycoside antibiotic in the active site of an amino
121 ransferases mediate high level resistance to aminoglycoside antibiotics in Gram-positive microorganis
122 The specificity of neomycin B and related aminoglycoside antibiotics in their interaction with the
123 on-derived kinase that confers resistance to aminoglycoside antibiotics, in Escherichia coli under se
126 xy alkyl modification of a readily available aminoglycoside antibiotic increases the inherent antibac
127 we show that subinhibitory concentrations of aminoglycoside antibiotics induce biofilm formation in P
128 ression in the chicken basilar papilla after aminoglycoside antibiotic-induced hair cell loss using R
129 recently showed that vaginal application of aminoglycoside antibiotics induces robust activation of
130 t intranasal delivery of neomycin, a generic aminoglycoside antibiotic, induces the expression of int
132 l subunit RNA of the bacterial ribosome, the aminoglycoside antibiotics inhibit protein synthesis, ca
137 hypothesis that the ototoxicity produced by aminoglycoside antibiotics involves the excitotoxic acti
138 initial loss of function due to exposure to aminoglycoside antibiotics is independent of the vascula
139 most serious side-effect of the widely used aminoglycoside antibiotics is irreversible intracellular
141 ays a significant role in resistance against aminoglycoside antibiotics, is controlled by a translati
142 ete proton and carbon NMR assignments of the aminoglycoside antibiotic isepamicin at pH 6.8 as well a
145 show that the binding of this RNA target to aminoglycoside antibiotics, its cognate ligands, can be
149 sreading, we asked if streptomycin (Str), an aminoglycoside antibiotic known to promote mistranslatio
151 adthrough-inducing drugs, such as repurposed aminoglycoside antibiotics, may represent a valuable the
156 f nuclear translocation of angiogenin by the aminoglycoside antibiotic neomycin inhibited PC-3 cell t
157 his report, we show that a derivative of the aminoglycoside antibiotic neomycin, in which all of the
158 mprove survival of hair cells exposed to the aminoglycoside antibiotic neomycin, whereas inhibition o
159 r the acridine derivative CGP 40336A and the aminoglycoside antibiotic neomycin, which bind to differ
160 interactions that govern the binding of the aminoglycoside antibiotics neomycin and kanamycin B to A
161 aration of a series of four analogues of the aminoglycoside antibiotics neomycin and paromomycin is d
162 echniques to characterize the binding of the aminoglycoside antibiotics neomycin, paromomycin, and ri
164 ANG's nuclear translocation by neomycin, an aminoglycoside antibiotic (not G418-neomicin), resulted
166 a recent trend in evolution of resistance to aminoglycoside antibiotics, of which four examples have
168 e side effect for many patients treated with aminoglycoside antibiotics or platinum-containing chemot
169 ting cells that express the mRNA with either aminoglycoside antibiotics or several nonantibiotic comp
170 to characterize the interaction between the aminoglycoside antibiotic paromomycin and a small model
172 The mof4-1 strain is more sensitive to the aminoglycoside antibiotic paromomycin than a upf1 delta
176 f aminosugars, from which a novel library of aminoglycoside antibiotics (pyranmycins) was synthesized
177 ng the efficacy of PTC124 with the classical aminoglycoside antibiotic read-through agent geneticin (
178 of high RNA target selectivity displayed by aminoglycoside antibiotics results from both their elect
181 ronically blocking calcium channels with the aminoglycoside antibiotic streptomycin from onset of dis
182 hacrynic acid (EA) is known to interact with aminoglycoside antibiotics such as gentamicin (GM).
183 ow that calcineurin mutants are sensitive to aminoglycoside antibiotics such as hygromycin B while pm
190 Neomycin is a large, positively charged, aminoglycoside antibiotic that has previously been shown
191 in RGS4, similar to those contained in some aminoglycoside antibiotics that are known to bind coatom
193 an improved understanding of how amphiphilic aminoglycoside antibiotics that bind to negatively charg
195 ptamine) is the most conserved element among aminoglycoside antibiotics that bind to the A-site.
197 tion confers resistance to a subclass of the aminoglycoside antibiotics that contain a 6' amino group
198 S rRNA A-site model oligonucleotide and four aminoglycoside antibiotics that exhibit a broad range of
200 characterize the binding of three classes of aminoglycoside antibiotics to ribosomal RNA subdomains.
201 useful to rapidly evaluate the potential of aminoglycoside antibiotics, to inhibit the Rev-RRE inter
202 RNA aptamer (J6RNA) selected to bind to the aminoglycoside antibiotic tobramycin is shown to do so w
204 been selected which were able to bind to the aminoglycoside antibiotic tobramycin with high affinity.
205 echniques to characterize the binding of the aminoglycoside antibiotic, tobramycin, to the polymeric
206 r undergo apoptosis after acoustic trauma or aminoglycoside antibiotic treatment, causing permanent a
208 ility to fluoroquinolone, cephalosporin, and aminoglycoside antibiotics using disk diffusion assays.
209 d 4,5-disubstituted 2-deoxystreptamine class aminoglycoside antibiotics was predicted and was borne o
211 he antibacterial activity of kanamycin class aminoglycoside antibiotics, we have accomplished the syn
212 he enzyme that modifies the essential N3B of aminoglycoside antibiotics, were determined by NMR spect
213 ues of the amino functions in a target-bound aminoglycoside antibiotic, which permitted dissection of
214 The decoding process is perturbed by the aminoglycoside antibiotics, which also interact with thi
221 doribostamycin resulting in the synthesis of aminoglycoside antibiotics with activity against drug-re
222 py has been used to study the interaction of aminoglycoside antibiotics with an aminoglycoside antibi
223 romising avenue for the development of novel aminoglycoside antibiotics with improved efficacy and re
224 B-DNA structures by conjugating neomycin, an aminoglycoside antibiotic, with the B-DNA minor groove b
225 B-DNA structures by conjugating neomycin, an aminoglycoside antibiotic, with the B-DNA minor groove b